Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IPH5201

Monoclonal antibody · Antagonist of CD39 (ectonucleoside triphosphate diphosphohydrolase-1) (ENTPD1) · developed by Innate Pharma

Phase 2 Most advanced trial
IPHA Developer
1 Registered trials

What is IPH5201?

IPH5201 is a monoclonal antibody that binds the cell surface ectonucleosidase CD39, blocking its conversion of extracellular ATP to AMP and thereby raising ATP and lowering immunosuppressive adenosine in the tumor microenvironment. It is being studied in non-small cell lung cancer, in combination with durvalumab and standard chemotherapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
CD39 (ectonucleoside triphosphate diphosphohydrolase-1) (ENTPD1)
Mechanism
Antagonist of CD39 (ectonucleoside triphosphate diphosphohydrolase-1) (ENTPD1)
Pathways
ATP-to-adenosine conversion, adenosine-mediated immunosuppression, T-cell proliferation, dendritic cell stimulation
Therapy area
Oncology
Developer
Innate Pharma (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05742607 Phase 2 Non Small Cell Lung Cancer Recruiting IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Small Cell Lung Cancer

Other drugs acting on ENTPD1

More from Innate Pharma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind IPH5201

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.